Emergent BioSolutions Initiates Phase 1b Study of TRU-016 in Combination with Rituximab

Emergent BioSolutions (NYSE: EBS) announced today the initiation of
a Phase 1b study (Protocol 16009) of TRU-016 in combination with
rituximab for patients with previously untreated chronic lymphocytic
leukemia (CLL). TRU-016 is a humanized anti-CD37 mono-specific protein
therapeutic in development for the treatment of B-cell malignancies.

“Preclinical studies have shown increased anti-tumor activity for the
combination of TRU-016 and rituximab beyond the levels achieved when
either drug was administered alone,” said Scott C. Stromatt, M.D.,
Senior Vice President and Chief Medical Officer, Emergent BioSolutions.
“We look forward to clinical evaluation of the effect of TRU-016 in
combination with rituximab in previously untreated CLL patients.”

The Phase 1b,

See full press release